Human pharmacokinetics prediction with an in vitro-in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection - Subramanian, Raju; Wang, Jianhong; Murray, Bernard; Custodio, Joseph; Hao, Jia; Lazerwith, Scott; MacLennan Staiger, Kelly; Mwangi, Judy; Sun, Hailing; Tang, Jennifer; Wang, Kelly; Rhodes, Gerry; et al. (Xenobiotica, 2022)
Keywords: Amides; Bictegravir; Drug Interactions; drug-drug interaction potential; Heterocyclic Compounds, 3-Ring - pharmacokinetics; HIV Infections - drug therapy; HIV Integrase Inhibitors - pharmacokinetics; HIV-1; human pharmacokinetics prediction; Humans; in vitro-in vivo correction factor; Pyridones; single-tablet combination regimen; HIV-1; in vitro–in vivo correction factor; drug-drug interaction potential; single-tablet combination regimen; Bictegravir; human pharmacokinetics prediction